CION Ameerpet
An astrocytoma is a glioma that starts in the brain's support cells. Its grade — and its IDH mutation status — shapes everything that follows. This guide explains the grades clearly and how CION's neuro-oncology team plans care.
An astrocytoma is a type of glioma — a brain tumour that begins in the astrocytes, the star-shaped support cells of the brain and spinal cord. "Astro" means star, which is how these tumours got their name. Astrocytomas are the most common group of gliomas, and they vary enormously: some are slow-growing and curable, others are aggressive.
The single most useful thing to understand about an astrocytoma is its grade — a number from 1 to 4 set by the World Health Organization (WHO). The grade describes how abnormal the cells look and how fast the tumour tends to grow. Today, the grade is read alongside molecular markers such as IDH mutation status, which together define the exact diagnosis. The grade and markers shape the whole treatment plan and the likely outlook.
This guide walks through the grades one by one, explains why IDH status matters, and sets out how astrocytomas are diagnosed and treated. For the full picture of brain tumour care, see our Brain Cancer & Tumour hub and our Brain Tumor Treatment in Hyderabad page.
The 2021 WHO Classification of Tumours of the Central Nervous System changed how astrocytomas are diagnosed — grade is now combined with molecular markers, especially the IDH gene mutation. Because of this, a grade 4 astrocytic tumour without an IDH mutation (IDH wild-type) is now classified as glioblastoma, while one with the mutation is named "astrocytoma, IDH-mutant, grade 4". The tissue test, not just the scan, now defines the diagnosis. (Source: WHO CNS5 classification, as referenced in NCCN and EANO glioma guidelines.)
Astrocytomas are graded, not staged. The grade reflects how the tumour cells look under the microscope and how quickly they grow — not how far they have spread, because brain tumours rarely spread to other organs.
| WHO Grade | Common Name | Behaviour | Typical Treatment |
|---|---|---|---|
| Grade 1 | Pilocytic astrocytoma | Very slow-growing, usually benign; most common in children; well-defined edges | Surgery alone is often curative |
| Grade 2 | Diffuse astrocytoma | Slow-growing but infiltrates normal brain; can progress to a higher grade over years | Surgery, then watch-and-wait or radiation & chemotherapy by risk |
| Grade 3 | Anaplastic astrocytoma | Malignant; grows more quickly than grade 2 | Surgery + radiation + chemotherapy |
| Grade 4 | Astrocytoma IDH-mutant grade 4 / Glioblastoma (IDH wild-type) | Most aggressive; fast-growing and infiltrative | Surgery + concurrent chemoradiation + adjuvant chemotherapy |
Grades and outcomes vary by individual; this table is a general guide. The grade is decided by a neuropathologist on tissue, not by a scan alone. Grading and naming follow the 2021 WHO classification and NCCN/EANO guidance.
Different astrocytomas behave very differently. Knowing the exact type — confirmed on tissue and molecular testing — is what lets the team tailor treatment precisely.
The most common brain tumour in children, though it can occur in young adults. It is slow-growing, usually benign, and has relatively well-defined edges. Because it does not deeply infiltrate normal brain, surgery to remove it is often curative. When it sits in a hard-to-reach area, radiation or close monitoring may be used instead.
A low-grade but infiltrating tumour, most common in younger adults aged 20 to 45. It grows slowly, but its cells spread into surrounding brain, so it cannot always be completely removed. Many carry an IDH mutation, which is linked to a better outlook. Over years, a grade 2 astrocytoma can transform into a higher grade, so regular MRI monitoring is important.
A malignant astrocytoma that grows more quickly than grade 2. It is usually treated with surgery followed by radiation and chemotherapy. IDH status again strongly influences the outlook. Read more on our dedicated anaplastic astrocytoma (grade 3) page.
The most aggressive form. Under the current WHO classification, a grade 4 astrocytic tumour that is IDH wild-type is classified as glioblastoma, while an IDH-mutant grade 4 tumour is named "astrocytoma, IDH-mutant, grade 4" — and usually grows more slowly than glioblastoma. Both need intensive, coordinated treatment.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Just received an astrocytoma diagnosis, want to understand what your grade and IDH status mean, or need a second opinion before treatment? CION's neuro-oncology team is here.
Symptoms depend on where the astrocytoma sits and how fast it grows, because different parts of the brain control different functions. Slow-growing grade 1 and 2 tumours may cause subtle, gradual symptoms; higher-grade tumours can cause symptoms that appear and worsen more quickly. Common warning signs include:
These symptoms have many ordinary causes and most are not a tumour. But a symptom that is new, persistent and steadily progressive — or a first adult seizure — should always be checked with a brain MRI. Speak to a CION neuro-oncologist if you have these signs or a confirmed astrocytoma.
Diagnosing an astrocytoma — and pinning down its exact grade and type — takes a step-by-step pathway. CION delivers the imaging, biopsy coordination, molecular testing and review directly.
MRI is the gold standard for finding and characterising an astrocytoma. With gadolinium contrast, it shows the tumour's location, size, edges and relationship to critical areas, and offers clues to the likely grade. Specialised sequences — perfusion MRI and spectroscopy — add information about blood flow and tumour activity.
Imaging can strongly suggest an astrocytoma, but only a tissue sample confirms the diagnosis, the exact type, and the grade. Tissue is obtained either during surgical removal or through a stereotactic needle biopsy — the surgical steps coordinated with accredited neurosurgical partners. A neuropathologist then grades the tumour.
On the tissue sample, molecular markers are tested. IDH mutation status is now part of the diagnosis itself and is the strongest prognostic marker in astrocytoma. For higher-grade tumours, MGMT methylation helps predict the benefit of alkylating chemotherapy. NCCN and EANO guidelines expect this molecular information before the full plan is finalised. CION arranges IDH and MGMT testing as standard on astrocytoma tissue.
In astrocytoma, the IDH gene mutation is the single most powerful indicator of how a tumour is likely to behave. Per EANO and NCCN guidance, IDH-mutant astrocytomas generally grow more slowly and carry a better outlook than IDH wild-type tumours of the same appearance — so much so that an IDH wild-type grade 4 astrocytic tumour is reclassified as glioblastoma. This is why a tissue molecular test, not just an MRI, should guide every astrocytoma treatment plan.
The treatment plan depends on the grade, location, IDH status and your overall health. Every astrocytoma is reviewed by CION's multidisciplinary tumour board before the plan is set. The main building blocks are:
For most astrocytomas, the first step is to remove as much tumour as is safely possible — called maximal safe resection. The extent of removal is one of the strongest predictors of outcome. CION coordinates the surgical step with accredited neurosurgical partners; the planning, molecular testing, radiation and follow-on care are managed directly by our team. For a grade 1 pilocytic astrocytoma, complete surgical removal is often curative on its own.
For grade 2 tumours with higher-risk features and for grade 3 and 4 tumours, radiation therapy is usually given after surgery. CION delivers precision radiation — IMRT and IGRT — directly, shaping the beam to the tumour bed while sparing healthy brain. For selected small or deep tumours, focused radiosurgery may be discussed as part of coordinated specialist radiation care.
Higher-grade astrocytomas are often treated with alkylating chemotherapy alongside or after radiation. CION's medical oncology team delivers systemic therapy directly and uses MGMT methylation status to inform the decision. Steroid and anti-seizure medicines, and supportive and rehabilitation care, are also managed in-house.
Some small, low-grade astrocytomas — particularly after a complete or near-complete removal — may be carefully monitored with regular surveillance MRI rather than treated immediately. This avoids the side effects of treatment while the tumour is stable, with a clear plan to step in if it changes.
An astrocytoma diagnosis carries a lot of nuance, and a second opinion is especially valuable in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's neuro-oncology tumour board — especially valuable if IDH and MGMT testing has not yet been arranged on your astrocytoma.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.An astrocytoma is a type of glioma — a brain tumour that begins in the astrocytes, the star-shaped support cells of the brain and spinal cord. Astrocytomas range from very slow-growing tumours that are often curable to fast-growing, malignant ones. They are graded 1 to 4 by the World Health Organization (WHO) based on how the cells look under the microscope and how quickly they grow. Astrocytomas can occur in both children and adults, though the common types differ by age. The grade — together with molecular markers found on the tumour tissue — guides the whole treatment plan and the likely outlook.
Astrocytomas are graded on a WHO scale of 1 to 4. Grade 1 (pilocytic astrocytoma) is slow-growing, usually benign, most common in children, and often curable with surgery alone. Grade 2 (diffuse astrocytoma) grows slowly but spreads into nearby brain tissue, so it can progress over years. Grade 3 (anaplastic astrocytoma) is malignant and more aggressive. Grade 4 is the most aggressive — when it is IDH wild-type it is classified as glioblastoma. The higher the grade, the faster the growth and the more intensive the treatment. The grade is decided by a neuropathologist, not by a scan alone.
It depends on the grade. A grade 1 pilocytic astrocytoma is generally benign (not cancerous) and very slow-growing — often cured by surgery. Grade 2 astrocytomas are low-grade but are not fully benign, because they infiltrate normal brain and can change into a higher grade over time. Grade 3 and grade 4 astrocytomas are malignant — that is, brain cancer. So the word "astrocytoma" covers a wide spectrum, from a curable benign tumour to an aggressive cancer. This is exactly why an accurate grade and molecular testing matter so much: they tell you which end of that spectrum a particular tumour sits on.
Since the 2021 WHO classification, the IDH gene mutation is part of the diagnosis itself, not just an extra detail. IDH-mutant astrocytomas tend to grow more slowly and have a meaningfully better outlook than IDH wild-type tumours of the same appearance. In fact, a grade 4 astrocytoma that is IDH wild-type is classified and treated as glioblastoma. IDH testing is done on the biopsy or surgical tissue. According to NCCN and EANO guidelines, this molecular information should be available before the full treatment plan is finalised. At CION, IDH testing is arranged as standard on astrocytoma tissue.
Treatment depends on the grade, location and IDH status. For most astrocytomas, the first step is maximal safe surgical removal — performed in coordination with accredited neurosurgical partners. After surgery, low-grade tumours may be watched with regular MRI, or treated with radiation therapy (IMRT/IGRT) and alkylating chemotherapy depending on risk features. Higher-grade astrocytomas are usually treated with radiation plus chemotherapy after surgery. CION delivers the radiation, systemic (drug) therapy, molecular testing, steroid and seizure management, and supportive care directly, and coordinates the surgical step. Every case is reviewed by a multidisciplinary tumour board before the plan is set.
Both are gliomas, and glioblastoma is essentially the most aggressive end of the astrocytoma family. Under the current WHO classification, a grade 4 astrocytic tumour that is IDH wild-type is named glioblastoma, while a grade 4 tumour that is IDH-mutant is called "astrocytoma, IDH-mutant, grade 4". The practical point is that IDH-mutant grade 4 astrocytomas usually grow more slowly and carry a better outlook than glioblastoma. Lower-grade astrocytomas (grades 1 to 3) are distinct, less aggressive tumours. Getting the exact name right — through neuropathology and molecular testing — directly changes the treatment plan and the expected outlook.
Growth speed tracks closely with the grade. A grade 1 pilocytic astrocytoma may stay almost unchanged for years. A grade 2 diffuse astrocytoma grows slowly but steadily, often over several years, and can transform into a higher grade. Grade 3 and grade 4 astrocytomas grow much faster, sometimes over weeks to months. Because lower-grade astrocytomas can change over time, doctors monitor them with periodic MRI scans even when no immediate treatment is given. Any new or worsening symptom — a fresh seizure, new weakness, or a steadily worsening headache — should prompt a prompt scan and review rather than waiting.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.